ANI Pharmaceuticals, Inc.
http://www.anipharmaceuticals.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ANI Pharmaceuticals, Inc.
Boehringer Looks To Revitalise Its Pipeline
With sales of its big sellers Jardiance and Ofev to start shrinking in the next few years, the German group is teeing up a suite of new drugs.
Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens
Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.
AstraZeneca’s Hot Streak Whets Investor Appetite For What’s Next
Outstanding Q1 growth in sales and profits have pleased the markets, and investors are now keen to hear more about AstraZeneca’s 2030 masterplan at its investor day next month.
AstraZeneca Looks To Many Modalities In Cancer
Mohit Manrao, head of AstraZeneca’s US oncology business unit, explained the company’s diverse approach in an interview, including investments in ADCs, cell therapy and radiopharmaceuticals.
Company Information
- Industry
- Contract Research Organization-CRO
- Services
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- BioSante Pharmaceuticals, Inc.
- Cell Genesys, Inc.
- Novitium Pharma LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice